Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S-Ethylisothiouronium diethylphosphate - TrioxBio

Drug Profile

S-Ethylisothiouronium diethylphosphate - TrioxBio

Alternative Names: Difetur; MTR 104; MTR-105; MTR-106; MTR-107; MTR-108; Nitric oxide synthase inhibitors - TrioxBio; Raviclust; Ravimig; Raviten

Latest Information Update: 06 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meditor Pharmaceuticals
  • Developer TrioxBio
  • Class Antihypotensives; Antimigraines; Phosphates; Urea compounds
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Intradialytic hypotension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypotension
  • Discontinued Intradialytic hypotension; Migraine

Most Recent Events

  • 29 May 2018 MTR 107 receives Fast Track designation for Intradialytic hypotension [IV, Injection] in USA
  • 29 May 2018 TrioxBio plans a phase II trial of MTR 107 for Intradialytic hypotension in USA in the fourth quarter of 2018
  • 31 Dec 2017 TrioxBio plans a phase II trial of MTR 106 for migraine in the US and Europe (TrioxBio Website, May 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top